Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology · Epithelial Ovarian Cancer

Biology & Subtypes: The 5 Faces of Ovarian Cancer

At a Glance

Ovarian cancer consists of five distinct subtypes, each with its own unique biology and genetic markers. Identifying your exact subtype through biopsy tests like WT1 allows your oncology team to create a highly personalized and targeted treatment plan.

While the diagnosis “ovarian cancer” may sound like a single disease, it is actually a collection of five distinct “faces” or histotypes. Each histotype has its own unique biology, genetic “fingerprint,” and typical response to treatment [1][2]. Because these are essentially different diseases, your care team will use your specific subtype to build a personalized roadmap for your care [3].

The Five Faces of Ovarian Cancer

1. High-Grade Serous Carcinoma (HGSOC)

This is the most common subtype. Its biology is almost always defined by a mutation in the TP53 gene, which acts as a “master switch” for cell growth [4]. Many of these tumors also have Homologous Recombination Deficiency (HRD)—a state where the cancer cells have trouble repairing their DNA [5][6].

  • Key Genetic Markers: TP53, BRCA1/2, and HRD [7][6].
  • Typical Response: Often responds well to platinum-based chemotherapy and targeted drugs called PARP inhibitors [5].

2. Low-Grade Serous Carcinoma (LGSOC)

Despite the name, this is a completely different disease from HGSOC. It tends to grow more slowly and often affects younger patients [8]. It is driven by the MAPK pathway, a signaling route that tells cells to divide [9].

  • Key Genetic Markers: KRAS, BRAF, and NRAS [9][10].
  • Typical Response: While it may be less sensitive to traditional chemotherapy, it often responds well to hormone-based (endocrine) therapies [11].

3. Endometrioid Carcinoma

This subtype is frequently associated with endometriosis [12]. It often has a better outlook because it is frequently caught at an earlier stage [13].

  • Key Genetic Markers: PTEN, PIK3CA, and ARID1A [14].
  • Lynch Syndrome Connection: Some of these tumors are linked to Lynch Syndrome (a hereditary condition) through Mismatch Repair deficiency (MMRd) [12][3].

4. Clear Cell Carcinoma (CCOC)

Like the endometrioid subtype, clear cell carcinoma is strongly linked to endometriosis [15][16]. It is unique because it can be more resistant to standard chemotherapy, making specialized treatment plans vital [13][16].

  • Key Genetic Markers: ARID1A (mutated in about 50% of cases) and PIK3CA [17][16].

5. Mucinous Carcinoma

This is a rare subtype where the cells produce a mucus-like substance. Doctors must carefully check to ensure the cancer started in the ovary and didn’t spread there from the appendix or colon [18].

  • Key Genetic Markers: Frequent mutations in KRAS and HER2 amplification [19][9].

How Doctors Confirm Your “Face”: The WT1 Test

To distinguish between these five faces, pathologists use immunohistochemistry (IHC). This process uses special stains directly on the tumor tissue removed during your biopsy or surgery (this is not an extra blood test) to see which proteins are “turned on” in the tumor [20].

One of the most important markers is WT1 (Wilms Tumor Protein 1) [21].

  • WT1 Positive: If the tumor stains positive for WT1, it strongly suggests a serous subtype (either high-grade or low-grade) [21][20].
  • WT1 Negative: If the tumor is negative for WT1, it points the doctor toward the non-serous types, like clear cell, endometrioid, or mucinous [20].

By combining the WT1 result with other markers, your medical team can confirm your exact subtype with high precision, ensuring you receive the most effective treatment for your specific “face” of the disease [20][22].

Genetic Testing for You and Your Family

Because markers like BRCA and Lynch Syndrome are hereditary, your care team should strongly recommend genetic counseling and testing. A simple blood or saliva test can determine if your cancer is linked to an inherited gene. This knowledge is crucial for tailoring your own targeted treatment and provides vital information regarding cancer risk for your biological relatives [23].

Common questions in this guide

What are the 5 main types of ovarian cancer?
The five main types, or histotypes, of ovarian cancer are high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. Each type has distinct genetic markers and responds differently to treatments.
What does the WT1 test mean for an ovarian cancer diagnosis?
The WT1 test uses a special stain on your tumor biopsy tissue to help identify your specific type of ovarian cancer. A positive WT1 result usually indicates a serous subtype, while a negative result points toward non-serous types like clear cell or endometrioid.
How does my ovarian cancer subtype affect my treatment?
Because each subtype behaves differently and has unique genetic mutations, your oncologist uses your specific histotype to build a personalized treatment plan. For example, high-grade serous tumors may be treated with PARP inhibitors, while low-grade serous tumors often respond better to hormone therapies.
Should I get genetic testing if I have ovarian cancer?
Yes, genetic testing is strongly recommended for ovarian cancer patients. Uncovering hereditary mutations like BRCA or Lynch Syndrome helps your doctors tailor your targeted treatments and informs your biological family members about their potential cancer risks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of the five major histotypes is my tumor, and how was this confirmed?
  2. 2.What was the result of my WT1 staining, and how did it help confirm my diagnosis?
  3. 3.Has my tumor been tested for specific mutations like TP53, BRCA, or ARID1A?
  4. 4.Is my treatment plan specifically tailored to my histotype, or is it a general approach?
  5. 5.Should I be screened for Lynch syndrome based on my subtype (if endometrioid or clear cell)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

    Oaknin A, Guarch R, Barretina P, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018; (20(3)):274-285 doi:10.1007/s12094-017-1719-x.

    PMID: 28815456
  2. 2

    Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.

    Craig O, Nigam A, Dall GV, Gorringe K

    Cold Spring Harbor perspectives in medicine 2023; (13(9)) doi:10.1101/cshperspect.a038190.

    PMID: 37277207
  3. 3

    Seeing beyond the tumor: computed tomography image-based radiomic analysis helps identify ovarian clear cell carcinoma subtype in epithelial ovarian cancer.

    Ren J, Mao L, Zhao J, et al.

    La Radiologia medica 2023; (128(8)):900-911 doi:10.1007/s11547-023-01666-x.

    PMID: 37368228
  4. 4

    Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.

    Wu RC, Wang P, Lin SF, et al.

    The Journal of pathology 2019; (248(1)):41-50 doi:10.1002/path.5219.

    PMID: 30560554
  5. 5

    Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.

    Hlaváč V, Holý P, Václavíková R, et al.

    Life science alliance 2022; (5(12)) doi:10.26508/lsa.202201551.

    PMID: 36229065
  6. 6

    Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1/2 and HRD status.

    Cruz GI, Kane KL, Matsuno RK, et al.

    The oncologist 2025; (30(8)) doi:10.1093/oncolo/oyaf100.

    PMID: 40796115
  7. 7

    Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.

    Ratajska M, Koczkowska M, Żuk M, et al.

    Oncotarget 2017; (8(60)):101325-101332 doi:10.18632/oncotarget.20722.

    PMID: 29254167
  8. 8

    Low-Grade Serous Carcinoma of the Ovary: The Current Status.

    Babaier A, Mal H, Alselwi W, Ghatage P

    Diagnostics (Basel, Switzerland) 2022; (12(2)) doi:10.3390/diagnostics12020458.

    PMID: 35204549
  9. 9

    Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.

    Murawski M, Jagodziński A, Bielawska-Pohl A, Klimczak A

    Cells 2024; (13(4)) doi:10.3390/cells13040345.

    PMID: 38391958
  10. 10

    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

    Monk BJ, Grisham RN, Banerjee S, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(32)):3753-3762 doi:10.1200/JCO.20.01164.

    PMID: 32822286
  11. 11

    Endocrine therapy in epithelial ovarian cancer.

    Langdon SP, Gourley C, Gabra H, Stanley B

    Expert review of anticancer therapy 2017; (17(2)):109-117 doi:10.1080/14737140.2017.1272414.

    PMID: 27967255
  12. 12

    Two possible entities of endometriosis-associated ovarian cancer: correlated or incidental?

    Mezzapesa F, Dondi G, Coada CA, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025; (35(4)):101634 doi:10.1016/j.ijgc.2025.101634.

    PMID: 39955191
  13. 13

    Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.

    Lee JY, Kim S, Kim YT, et al.

    BMC cancer 2018; (18(1)):601 doi:10.1186/s12885-018-4498-z.

    PMID: 29843633
  14. 14

    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

    Martins FC, Couturier DL, Paterson A, et al.

    British journal of cancer 2020; (123(5)):793-802 doi:10.1038/s41416-020-0900-0.

    PMID: 32555365
  15. 15

    Endometriosis-Related Ovarian Cancer: Where Are We Now? A Narrative Review towards a Pragmatic Approach.

    Centini G, Schettini G, Pieri E, et al.

    Journal of clinical medicine 2024; (13(7)) doi:10.3390/jcm13071933.

    PMID: 38610698
  16. 16

    Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

    Blanc-Durand F, Ngoi N, Lim D, et al.

    Cancer treatment reviews 2025; (138()):102977 doi:10.1016/j.ctrv.2025.102977.

    PMID: 40517636
  17. 17

    Tumor Immune Microenvironment and Checkpoint Inhibition in Clear Cell Ovarian Carcinoma: Bridging Tumor Biology and Clinical Application in Immunotherapy.

    Borella F, Capella G, Cosma S, et al.

    Current issues in molecular biology 2025; (47(9)) doi:10.3390/cimb47090726.

    PMID: 41020848
  18. 18

    Mucinous Ovarian Carcinoma.

    Morice P, Gouy S, Leary A

    The New England journal of medicine 2019; (380(13)):1256-1266 doi:10.1056/NEJMra1813254.

    PMID: 30917260
  19. 19

    Targeting RAS-RAF-MEK-ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework.

    Bartl T, Cacsire Castillo-Tong D

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(4)):104485 doi:10.1016/j.ijgc.2026.104485.

    PMID: 41680018
  20. 20

    Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis.

    Manu V, Hein TA, Boruah D, Srinivas V

    Medical journal, Armed Forces India 2020; (76(1)):30-36 doi:10.1016/j.mjafi.2018.06.014.

    PMID: 32020965
  21. 21

    Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.

    Taube ET, Denkert C, Sehouli J, et al.

    Gynecologic oncology 2016; (140(3)):494-502.

    PMID: 26721227
  22. 22

    Serous endometrial cancer with an elusive preoperative diagnosis.

    Rajaram S, Singh L, - B, Nagar S

    BMJ case reports 2026; (19(3)) doi:10.1136/bcr-2025-270356.

    PMID: 41813027
  23. 23

    Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer.

    Luo Y, Pan R, Rao H, et al.

    International journal of general medicine 2024; (17()):75-84 doi:10.2147/IJGM.S445660.

    PMID: 38226182

This page provides educational information about ovarian cancer subtypes and genetics. Always consult your oncologist or gynecologic pathologist for medical advice tailored to your specific diagnosis.

Get notified when new evidence is published on Malignant epithelial tumor of ovary.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.